Equity, IP, and Conflicts of Interest at a Biotech Consultancy

Consulting agreements in scientific and technical work vary widely on IP ownership, and it's a mistake to assume your firm automatically retains rights to a novel methodology, dataset, or analytical framework developed while working on a client engagement. Read every engagement contract's IP clause carefully, and if your firm wants to reuse a framework across multiple clients as its own intellectual property, negotiate that explicitly rather than assuming it by default.

This matters for equity specifically when a firm wants to spin a reusable tool or platform out as its own product, since a muddled IP history complicates any future outside investment in that spinoff.

Many scientific advisors at a consultancy like this also hold university or research institution appointments, and most institutions require faculty to disclose outside consulting income and any equity stakes above a set threshold, sometimes reviewed by a formal conflict-of-interest committee. An advisor granted firm equity without disclosing it to their institution risks a real compliance problem on their end, separate from anything the consultancy itself does.

Build a reminder into your onboarding process for any advisor who might hold an academic appointment, since it's a genuinely easy step to miss and a serious one to get wrong.

Some scientific advisors work through their university and may be restricted from personally holding equity in a company doing business with, or built on research from, that same institution, depending on the technology transfer agreement in place. Confirm this directly with the advisor and, where relevant, their institution's technology transfer office before finalizing a grant, rather than discovering a restriction after the paperwork is signed.

Where direct equity isn't possible, a consulting fee structure or a royalty arrangement tied to specific deliverables is often a workable alternative that doesn't run into the same restriction.

If your consultancy's work leads to a genuine product opportunity, whether a novel assay, a software platform, or a proprietary dataset, keep that spinout's cap table entirely separate from the parent consultancy's from day one. Mixing services-firm equity with product-entity equity confuses both the tax treatment and any future investor's diligence, and unwinding a mixed structure later is far more expensive than starting clean.

If you're a spinout raising a first outside round, you'll likely need a 409A valuation before issuing options, so compare Pulley's and Carta's current 409A turnaround and SAFE modeling features, since both were built for the startup case.

A scientific consultancy with meaningful IP or a product spinout in progress needs a 409A valuation firm that actually understands how to value that IP, not one that only knows how to model recurring services revenue. Ask directly about the valuation firm's experience with technical or life sciences IP before committing, since an inexperienced valuation can understate or overstate fair market value in ways that create real problems for option holders later.

Refresh the valuation after any material IP or licensing event, not just annually, given how much a single deal can move the number.

If a spinout entity is negotiating a licensing agreement with a pharmaceutical partner or a larger platform company at the same time it's finalizing equity for its founding scientists, keep the two workstreams from blocking each other. A licensing counterparty's own diligence team will want to see clean, resolved cap table records, so try to have equity questions settled before that negotiation reaches a serious stage rather than scrambling to finalize grants mid-deal.

This sequencing mistake, letting internal equity disputes surface during external deal negotiations, has derailed more than one promising licensing conversation in this field, and it's entirely avoidable with earlier planning. Build a simple pre-deal checklist that includes a cap table review alongside the usual financial and legal diligence items, so equity hygiene is never the thing discovered late in a process that's otherwise moving well.

Run through these checks before granting any equity:

• Read each engagement contract's IP clause before assuming the firm keeps rights to a methodology, dataset, or framework built for a client.
• Ask each advisor with a university or research appointment whether their institution requires disclosure of outside consulting income and equity stakes.
• Confirm with the advisor, and where relevant the technology transfer office, that they can legally hold equity before you finalize a grant.
• Keep any spinout's cap table fully separate from the consultancy's from day one.
• Ask a 409A valuation firm about its experience valuing technical or life sciences IP before you hire it.